City Therapeutics collected $99.5 million to advance clinical development for its first three RNAi candidates and extend the platform to targets beyond the liver. The fundraising comes as next-generation RNA interference companies push for differentiation around potency, delivery, and pipeline breadth. The company’s near-term focus is on gathering clinical data to validate dose-response, safety, and target engagement across early indications. The financing also supports expansion into additional therapeutic areas, reflecting investor demand for platform scalability. City’s raise adds to the wider funding momentum in RNAi, where competitors are increasingly targeting systemic delivery and broader tissue access.